Interesting, Good News for Impel NeuroPharma and Migraine Sufferers

Impel NeuroPharma FDA Approval for TRUDHESA
The U.S. Food and Drug Administration (FDA) approved Impel NeuroPharma (IMPL) product TRUDHESA (dihydroergotamine mesylate (DHE)), previously known as INP104, a nasal spray for the treatment of acute migraine with or without aura in adults.

Using Impel’s proprietary Precision Olfactory Delivery (POD®) technology enables a gentle, quick delivery of . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.